Robin van Geel
Overview
Explore the profile of Robin van Geel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
35
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hillege L, Barnett D, Ziemons J, Aarnoutse R, de Vos-Geelen J, van Geel R, et al.
Sci Rep
. 2025 Mar;
15(1):7874.
PMID: 40050324
Tamoxifen is essential in treating estrogen receptor-positive (ER+) breast cancer, primarily through its active metabolite, endoxifen. Emerging research suggests potential interactions between tamoxifen and gut microbiota. This study investigates the...
2.
Remon J, Bortolot M, Bironzo P, Cortiula F, Menis J, Brandao M, et al.
J Clin Oncol
. 2025 Jan;
43(9):1148-1156.
PMID: 39836933
Immune checkpoint blockers (ICBs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, with ICBs administered at flat...
3.
Gulikers J, Bruinsma J, Schoenmaekers J, Dursun S, Tjan-Heijnen V, van Geel R, et al.
Ther Adv Med Oncol
. 2024 Dec;
16:17588359241303403.
PMID: 39649018
Background: Tyrosine kinase inhibitors (TKIs) have significantly improved treatment-related outcomes of patients with oncogene-driven non-small-cell lung cancer (NSCLC). TKIs are usually well tolerated and used for a prolonged time, although...
4.
Ziemons J, Hillege L, Aarnoutse R, de Vos-Geelen J, Valkenburg-van Iersel L, Mastenbroek J, et al.
BMC Microbiol
. 2024 Jun;
24(1):222.
PMID: 38918717
Background: 5-Fluorouracil (5-FU) is used as an antineoplastic agent in distinct cancer types. Increasing evidence suggests that the gut microbiota might modulate 5-FU efficacy and toxicity, potentially affecting the patient's...
5.
van Veelen A, Gulikers J, Hendriks L, Dursun S, Ippel J, Smit E, et al.
Lung Cancer
. 2022 Aug;
171:97-102.
PMID: 35933915
Introduction: Exposure to osimertinib, a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for treatment of non-small cell lung cancer (NSCLC) and a sensitizing EGFR mutation, can...
6.
Oelen Y, Revenberg S, de Vos-Geelen J, van Geel R, Schoenmaekers J, van den Beuken-Everdingen M, et al.
J Cancer Res Clin Oncol
. 2022 Jul;
149(5):1863-1872.
PMID: 35779108
Purpose: Despite the inconclusiveness regarding health effects of cannabinoids among cancer patients, studies from non-European countries suggest that the medical-intended consumption of such products by this patient group is significant....
7.
van Veelen A, Abtahi S, Souverein P, Driessen J, Klungel O, Dingemans A, et al.
Cancer Epidemiol
. 2022 Apr;
78:102149.
PMID: 35429893
Introduction: In- and exclusion criteria of randomized clinical trials (RCTs) aim to include a homogeneous study-population. This study compared characteristics of lung cancer patients from phase III RCTs evaluating tyrosine...
8.
van Veelen A, van Geel R, Schoufs R, de Beer Y, Stolk L, Hendriks L, et al.
Biomed Chromatogr
. 2021 Aug;
35(12):e5224.
PMID: 34363425
A liquid chromatography-tandem mass spectrometry method was developed and validated to quantify alectinib, crizotinib, erlotinib and gefitinib. This assay can be combined with our method for osimertinib, allowing quantification of...
9.
van Brummelen E, Huijberts S, van Herpen C, Desar I, Opdam F, van Geel R, et al.
Oncologist
. 2020 Dec;
26(4):290-e545.
PMID: 33296125
Lessons Learned: Afatinib and selumetinib can be combined in continuous and intermittent dosing schedules, albeit at lower doses than approved for monotherapy. Maximum tolerated dose for continuous and intermittent schedules...
10.
van Veelen A, van Geel R, de Beer Y, Dingemans A, Stolk L, Ter Heine R, et al.
Biomed Chromatogr
. 2019 Dec;
34(4):e4771.
PMID: 31808583
A new method for quantification of osimertinib (OSIM) in human plasma using a high-performance liquid chromatography-tandem mass spectrometry method was developed and validated. Methanol was used for protein precipitation and...